Kenvue Inc. $KVUE Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.0% in the fourth quarter, HoldingsChannel reports. The firm owned 1,098,669 shares of the company’s stock after selling 70,627 shares during the period. Pictet Asset Management Holding SA’s holdings in Kenvue were worth $18,952,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in shares of Kenvue during the third quarter valued at approximately $25,000. NBT Bank N A NY grew its holdings in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC increased its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the period. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, Golden State Wealth Management LLC raised its stake in Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.5%

KVUE opened at $17.44 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The company has a market capitalization of $33.48 billion, a PE ratio of 22.65, a P/E/G ratio of 3.98 and a beta of 0.61. The stock’s fifty day moving average is $17.72 and its 200-day moving average is $17.17. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the previous year, the company earned $0.26 earnings per share. Kenvue’s revenue was up 3.2% compared to the same quarter last year. On average, equities analysts predict that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio is currently 107.79%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Canaccord Genuity Group increased their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Citigroup decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research report on Wednesday, April 8th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.